Skip to main content
OpenTrials
Completed

NCT Number: NCT05633264

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

EP Pharmaline

Tosima-ku, Tokyo, 171-0021, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Psoriasis (PsO) participants who received Deucravacitinib for the first time of the approved indications at medical institutions in Japan will be enrolled in this PMS

Exclusion criteria

  • Participants receiving Deucravacitinib for an off-label indication will be excluded from this PMS.

Treatment and study plan

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Proportion of participants achieving Static Physicians Global Assessment (sPGA) of 0/1 during study period

    Time frame: Up to 52 weeks

  2. Change from Baseline in Body Surface Area (BSA) during study period

    Time frame: Up to 52 weeks

  3. Proportion of participants achieving Global Improvement Score (GIS) during study period

    Time frame: Up to 52 weeks

  4. Distribution of demographic characteristics: Age

    Time frame: Up to 52 weeks

  5. Distribution of demographic characteristics: Sex

    Time frame: Up to 52 weeks

  6. Distribution of demographic characteristics: Height

    Time frame: Up to 52 weeks

  7. Distribution of demographic characteristics: Weight

    Time frame: Up to 52 weeks

  8. Distribution of demographic characteristics: Past history /complication

    Time frame: Up to 52 weeks

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Deucravacitinib Post-marketing Surveillance in Patients With Psoriasis in Japan

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Dec 1, 2022
Registry last updated
Jul 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.